As the speaker of the CFA Society Hong Kong’s webinar—"High-Risk, High-Reward? How to assess the value of a Biotech company?”

Our Managing Director, Mr. Vincent Pang was pleased to be invited by the CFA Society Hong Kong to speak on the “High-Risk, High-Reward? How to assess the value of a Biotech company?” webinar.

 

The webinar received around 180 registrations, gathering fellow CFAs that would like to better understand the valuation of biotechnology company under the surge of Biotech listings on HKEX due to the introduction of Chapter 18A of the Listing Rules in 2018.

 

Vincent introduced the attributes of biotechnology industry and its challenges to traditional valuation approaches, shared the valuation methods for biotechnology company with case studies, and highlighted the limitations of each method.

 

 

 

 

Date: 26 Mar 2021 | Tags: Business Valuation, Initial Public Offering (IPO)

Privacy & Disclaimer

© COPYRIGHT 2020 AVISTA GROUP, ALL RIGHTS RESERVED

沪ICP备17054339号